Constructio of a doxorubicin-containing liposomal system for effecting lung cancer

Ansari, Mojtaba; Estabraghi, Mohammad Amin; Haghirosadat, Bibi Fatemeh; Taebpour, Mohammad

Constructio of a doxorubicin-containing liposomal system for effecting lung cancer

Document Type : Original Research

Authors

Mojtaba Ansari ¹

Mohammad Amin Estabraghi ²

Bibi Fatemeh Haghirosadat ³

Mohammad Taebpour ³

¹ Meybod University

² Science and Art University

³ Shahid Sadoughi University of Medical Sciences

Abstract

Chemotherapy is one of the methods used in the treatment of cancer. Not being targeted has many side effects for the patient. The use of nano-carriers, including nano-liposomes, is a very effective way to target chemotherapy. In this study, a liposomal system containing doxorubicin was designed and evaluated for its effect on lung cancer cells.

In this in vitro study, two liposomal systems were prepared by the method of thin-film hydration and using different concentrations of phosphatidylcholine and cholesterol. Doxorubicin was then loaded into the systems. Finally, one of the systems was selected based on the drug loading rate and drug release pattern. At the end, the selected drug delivery system in terms of particle size, zeta potential, liposomal vesicle appearance, and the interaction between the drug and the system was investigated.

The selected liposomal system contains doxorubicin with an encapsulation efficiency of 58.89%, size of 273 nm, dispersion index of 0.458 and zeta potential of -35.7 mv. Doxorubicin release from liposomes was controlled and no chemical interaction was observed between liposomes and referees. Liposomal vesicles are also spherical and have a smooth surface.

The results of this study show that nano-liposomes can be prepared with appropriate formulation containing doxorubicin using nanotechnology. Which has good physicochemical properties. Therefore, this liposomal system can be recommended for further cancer-related research.

Keywords

Nano Liposomes

Doxorubicin

Cancer

Chemotherapy

20.1001.1.23222115.1401.13.2.6.1

Subjects

Nanotechnology

1. Pecorino L. Molecular biology of cancer: mechanisms, targets, and therapeutics: Oxford University Press, USA; 2016.
2. Cheong I, Zhou S. Tumor-specific liposomal drug release mediated by liposomase. Methods in enzymology. 2009;465:251-65.
3. Fitzmaurice C, Allen C, Barber RM, Barregard L, Bhutta ZA, Brenner H, et al. Global, regional, and national cancer incidence, mortality, years of life lost, years lived with disability, and disability-adjusted life-years for 32 cancer groups, 1990 to 2015: a systematic analysis for the global burden of disease study. JAMA oncology. 2017;3(4):524-48.
4. Liu C, Wen Z, Li Y, Peng L. Application of ThinPrep bronchial brushing cytology in the early diagnosis of lung cancer: a retrospective study. PLoS One. 2014;9(4):e90163.
5. Kumar V, Abbas A, Aster J. Environmental and nutritional diseases. Robbins and Cotran Pathologic Basis of Disease 9th ed Philadelphia, PA: Elsevier Saunders. 2015;433.
6. Hosseini M, Naghan PA, Karimi S, SeyedAlinaghi S, Bahadori M, Khodadad K, et al. Environmental risk factors for lung cancer in Iran: a case–control study. International journal of epidemiology. 2009;38(4):989-96.
7. Krishnaiah V, Narsimha G, Chandra NS. Diagnosis of lung cancer prediction system using data mining classification techniques. International Journal of Computer Science and Information Technologies. 2013;4(1):39-45.
8. Taghavi Holagh A, Aabednatanzi H, Badalzadeh R, Ghazalian F. The effect of Troxerutin combined with high intensity interval training on heart injury and expression of antioxidant genes in doxorubicin-induced cardiac toxicity in male rats. Daneshvar Medicine. 2021;29(2):79-90.
9. McEvoy G. Snow, ED, eds. AHFS: drug information Bethesda, MD: American Society of Health-System Pharmacists. 2008.
10. Kaufmann SH, Earnshaw WC. Induction of apoptosis by cancer chemotherapy. Experimental cell research. 2000;256(1):42-9.
11. Rivankar S. An overview of doxorubicin formulations in cancer therapy. Journal of cancer research and therapeutics. 2014;10(4):853.
12. Barenholz Y, Gabizon A. Liposome/doxorubicin composition and method. Google Patents; 1990.
13. Mirahmadi N, Babaei M, Vali A, Dadashzadeh S. Effect of liposome size on peritoneal retention and organ distribution after intraperitoneal injection in mice. International journal of pharmaceutics. 2010;383(1-2):7-13.
14. Keller BC. Liposomes in nutrition. Trends in food science & technology. 2001;12(1):25-31.
15. Moghimipour E, Kouchak M, Bahmandar R. Nano-liposomes as new Drug Delivery Carriers. Jundishapur Scientific Medical Journal. 2013;12(5):467-483.
16. Sirisha V, BhavaniHarika I, Sruthi B, Namrata M, Kirankumar P, Kiran Y, et al. Liposomes-the potential drug carriers. J Pharm. 2012;2(5):26-38.
17. Majdizadeh M, Rezaei Zarchi S, Movahedpour AA, Shahi Malmir H, Sasani E, Haghiralsadat BF. A new strategy in improving therapeutic indexes of medicinal herbs: preparation and characterization of nano-liposomes containing Mentha piperita essential oil. SSU_Journals. 2018;25(11):853-64.
18. Shahi Malmir H, Kalantar SM, Sasani E, Asgari M, Majdizadeh M,
Haghiralsadat BF. Synthesis and optimization of niosomal carriers containing doxorubicin in order to achieve a final formulation with high potential in cancer cells temperature and acidity. Journal of Shahid Sadoughi University of Medical Sciences. 15;26(10):879-94.
19. Baghiani M, Majdizadeh M, Haghiralsadat BF. Experimental study: experimental evaluation of phospholipid system containing doxorubicin HCL for use in chemotherapy. Journal of Shahid Sadoughi University of Medical Sciences. 2019.
20. Momo F, Fabris S, Stevanato R. Interaction of fluoxetine with phosphatidylcholine liposomes. Biophysical chemistry. 2005;118(1):15-21.
21. Honary S, Zahir F. Effect of zeta potential on the properties of nano-drug delivery systems-a review (Part 1). Tropical Journal of Pharmaceutical Research. 2013;12(2):255-64.
22. Zhang Y, Yang M, Portney NG, Cui D, Budak G, Ozbay E, et al. Zeta potential: a surface electrical characteristic to probe the interaction of nanoparticles with normal and cancer human breast epithelial cells. Biomedical microdevices. 2008;10(2):321-8.
23. Guo J, Bourre L, Soden DM, O'Sullivan GC, O'Driscoll C. Can non-viral technologies knockdown the barriers to siRNA delivery and achieve the next generation of cancer therapeutics? Biotechnology advances. 2011;29(4):402-17.
24. Dua J, Rana A, Bhandari A. Liposome: methods of preparation and applications. Int J Pharm Stud Res. 2012;3(2):14-20.
25. Tan ML, Friedhuber AM, Dunstan DE, Choong PF, Dass CR. The performance of doxorubicin encapsulated in chitosan–dextran sulphate microparticles in an osteosarcoma model. Biomaterials. 2010;31(3):541-51.
26. Ghanbari M. Ebrahimi Shaham Abadi H, Saffari Z & Akbarzadeh Khiyavi A. Pegilated nanoliposome New Cellular & Molecular Biotechnology Journal. 2016;6(21):35-40.
27. Naderinezhad S, Haghirosadat F, Amoabediny G, Naderinezhad A, Esmaili Z, Akbarzade A. Synthesis of biodegradable and self-assembled anionic nano–carrier: Novel approach for improvement of Curcumin-delivery to bone tumors cells & Mathematical modeling of drug-release kinetic. New Cellular and Molecular Biotechnology Journal. 2017;7(27):77-84.
28. Bahrami-Banan F, Sheikhha MH, Ghasemi N, Majdizadeh M, Haghiralsadat BF. Preparation and study of nano-niosomes containing doxorubicin and evaluation of its toxicity on acute myeloblastic leukemia cell line KG-1. Journal of Payavard Salamat. 2018;12(4):309-23.
29. Sasani E, Shahi Malmir H, Daneshmand F, Majdizadeh M, Haghiralsadat BF. A new study on synthesize and optimization of PEGylated LipoNiosomal nanocarriers containing curcumin for use in cancer chemotherapy. SSU_Journals. 2018;26(6):528-41.